Myriad Genetics (MYGN) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Myriad Genetics (MYGN) PT Raised to $23 at Jefferies
August 9, 2017 8:40 AM EDTJefferies raised its price target on Myriad Genetics (NASDAQ: MYGN) to $23.00 (from $21.00) while maintaining a Hold rating. MYGN's initial FY18 revenue outlook fell ~$30M below consensus, owing to ASP headwinds it will absorb in hereditary cancer from steps taken to secure LT, fixed-price... More
